The current case extends the observations on mediastinal bronchogenic cyst by demonstrating that bronchogenic cyst may result in life-threatening cardiovascular compromise. The sudden deterioration may have occurred secondary to fluid shifts within the mass secondary to rupture of an internal septum, as demonstrated at surgery. This change in cyst morphologic features could have resulted in compression of vital surrounding structures-the pulmonary arteries and left atrium-creating a tamponade-like presentation.
St. Georges et all recommended that all presumed bronchogenic cysts in adults be resected, because the majority of patients will become symptomatic or develop complications. 
CASE REPORT
A 64-year-old man who had a history of blood transfusion in 1953 was first suspected of having liver damage by chance in January 1992. He was diagnosed as having chronic hepatitis C by serologic findings and was treated with glycyrrhizin. However, his serum transaminase levels were worsening; aspartate aminotransferase was 244 IU/L, and alanine aminotransferase was 253 IU/L. His diagnosis of chronic active hepatitis was established by liver biopsy specimen in September 1992. He then received recombinant human alpha interferon (alpha-2b): 10 million units/d for 11 weeks, 6 days a week for the first 2 weeks and 3 days a week for 9 weeks, starting from the end of September. After 1 month, his serum transaminase levels decreased to within the normal range. In late November, he developed dyspnea, fever, and nonproductive cough.
No remarkable abnormality was found in the laboratory data except for an enhanced erythrocyte sedimentation rate (45 mm/ h). The white blood cell count was 5,900/mm3 (segmenteds 38 percent; stab, 1 percent; lymphocytes, 40 percent; monocytes, 12 (Table 1 ). An arterial blood gas analysis revealed moderate hypoxia. A fine crackle was audible diffused in both lungs. A chest radiograph demonstrated bilateral patchy infiltrates and reticulonodular opacities that had not been seen prior to the treatment with interferon (Fig 1) . Cultures of sputum and bronchial washing were negative for bacteria, fungi, and acid-fast bacilli. The total cell count in the bronchoalveolar lavage fluid was 1.7XI05/ml and the cell population consisted of macrophages (56 percent), neutrophils (1 percent), lymphocytes (40 percent), and eosinophils (3 percent). The ratio of CD4/CD8 was 0.10. Lung tissue was obtained by a thoracoscopic biopsy, and the pathologic findings indicated bronchiolitis obliterans with interluminal polyps and organizing pneumonia in the alveolar ducts (Fig 2) .
Administration of interferon was interrupted and treatment with prednisolone (40 mg/d) was started. The clinical symptoms of dyspnea and the radiographic infiltrates subsequently disappeared promptly within a week, and lung function returned to normal (Table 1) . Neither interferon nor any other treatment was given again, but his transaminase levels have remained within the normal range.
DISCUSSION
Epler et al,3 in 1985, provided the first description of BOOP as a clinicopathologic entity. Pathologic findings were granulation tissue plugs within the lumens of the small airways extending into the alveolar ducts and the alveoli. They classified BOOP as idiopathic or related to some disorder such as a viral infection, a connective tissue disease, focal, cocaine abuse, drug reaction, human immunodeficiency virus infection, myelodysplastic syndrome, or radiation therapy.4 Various therapeutic drugs have been reported to be responsible for causing BOOP. These have included acebutolol, amiodarone, bleomycin, cephalosporin, cocaine, gold, cyclophosphamide, methotrexate, mitomycin-C, penicillamine, sulfametopyrazine, sulfasalazine, and sulindac.1l5
Recombinant human alpha interferon is a protein with 165 amino acid residues. It has an antiviral activity and is currently being used in the treatment for chronic viral hepatitis. Recently, acute interstitial nephritis was reported as a side effect of such interferon use.2 Though several other minor side effects have also been reported, to our knowledge, there is no report describing the involvement of the lungs.
Our patient presented with chronic hepatitis C treated with interferon and developed dyspnea, fever, and cough with diffuse pulmonary infiltrates on chest radiographs. All these symptoms disappeared after the suspension of interferon therapy and treatment instead with prednisolone. He did not have any other medical disorders that could be associated with BOOP. We conclude that interferon itself is the suspected cause of the disorder, though we have no direct proof. The present report is the first (to our knowledge) to give additional attention to the use of interferon as possibly responsible for BOOP.
